Previous 10 | Next 10 |
HOLON, Israel , Jan. 29, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and leader in predictive target discovery, announced today that The European Patent Office (EPO) has granted the Company a new patent for the use of any anti-PV...
Compugen (NASDAQ: CGEN ) initiated with Overweight rating and $10 (73% upside) price target at Cantor Fitzgerald. Shares up 3% premarket. More news on: Compugen Ltd., Diplomat Pharmacy, Inc., GlaxoSmithKline plc, Healthcare stocks news, Stocks on the move, , Read more ...
Quick Take Schrödinger ( SDGR ) has filed to raise $100 million in an IPO of its common stock, according to an S-1 registration statement . The firm sells drug and compound discovery software to biopharmaceutical firms and other research organizations worldwide. SDGR is growing rev...
HOLON, Israel , Jan. 9, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today provided an update on upcoming milestones for its COM701 and COM902 clinical programs and highlighted...
HOLON, Israel , Jan. 8, 2020 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced the appointment of Oliver Froescheis, Ph.D., as Senior Vice President, Corporate and Bus...
HOLON, Israel , Dec. 20, 2019 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN), a clinical-stage cancer immunotherapy company and a leader in predictive target discovery, today announced that it has been selected for addition to the NASDAQ Biotechnology Index® (NASDAQ: ^NBI). Compug...
–Addition of Experienced Executive to Leadership Team– CAMBRIDGE, Mass. and MISSISSAUGA, Ontario, Dec. 12, 2019 (GLOBE NEWSWIRE) -- Janpix, Inc., a privately-held biopharmaceutical company dedicated to the discovery and development of inhibitors/degraders of Signal Transduce...
Image source: The Motley Fool. Compugen Ltd. (NASDAQ: CGEN) Q3 2019 Earnings Call Nov 11, 2019 , 8:30 a.m. ET Operator Continue reading
Compugen Ltd. (CGEN) Q3 2019 Earnings Conference Call November 11, 2019 8:30 AM ET Company Participants Elana Holzman - Director of Investor Relations & Corporate Communications Anat Cohen-Dayag - President & Chief Executive Officer Henry Adewoye - Chief Medical Officer ...
Compugen ( CGEN ) Q3 results : Revenues: $0; R&D Expense: $4.3M (-44.9%); SG&A: $2.4M (-11.1%); Net loss: ($6.5M) (-109.7%); loss/share: ($0.10) (-100.0%); Quick Assets: $47.6M (+4.2%). More news on: Compugen Ltd., Healthcare stocks news, Earnings news and commentary, Stocks on th...
News, Short Squeeze, Breakout and More Instantly...
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors PR Newswire FDA clearance triggers a $30 million milestone payment from Gilead Company on track to initiate a Phase 1 trial for COM503, a differentiated antibody approach to harne...
Compugen to Release Second Quarter 2024 Results on Tuesday, August 6, 2024 PR Newswire HOLON, Israel , July 23, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN) a clinical-stage cancer immunotherapy company and a pioneer in computational target ...
Compugen to Present at Upcoming Antibody Industrial Symposium PR Newswire HOLON, Israel , June 17, 2024 /PRNewswire/ -- Compugen Ltd. (Nasdaq: CGEN) (TASE: CGEN), a clinical-stage cancer immunotherapy company and a pioneer in computational target discovery, t...